Technical Analysis for FOLD - Amicus Therapeutics, Inc.

Grade Last Price % Change Price Change
grade C 13.46 -0.52% -0.07
FOLD closed down 0.52 percent on Tuesday, March 19, 2019, on 59 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Flat
See historical FOLD trend table...

Date Alert Name Type % Chg
Mar 19 MACD Bearish Signal Line Cross Bearish 0.00%
Mar 19 1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Mar 19 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Mar 18 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.52%
Mar 18 Outside Day Range Expansion -0.52%
Mar 15 180 Bullish Setup Bullish Swing Setup -2.68%
Mar 15 Pocket Pivot Bullish Swing Setup -2.68%
Mar 15 Inside Day Range Contraction -2.68%
Mar 15 Wide Bands Range Expansion -2.68%
Mar 14 Bearish Engulfing Bearish -0.52%

Older signals for FOLD ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs known as pharmacological chaperones. It develops pharmacological chaperones as next-generation medicines for a range of rare and orphan diseases with a focus on improved therapies for lysosomal storage disorders. The company's development programs include small molecules as monotherapy treatments for Fabry and other lysosomal storage diseases, and enzyme replacement therapy (ERT). Its chaperone-advanced replacement therapy programs comprise chaperones co-administered with currently marketed ERTs, as well as proprietary therapeutic enzymes co-formulated with pharmacological chaperones as next-generation ERTs. The company's primary product includes migalastat HCl, a product candidate for Fabry disease that is in Phase III global registration studies for patients with genetic mutations. Its products also comprise AT2220, which has completed Phase II safety used for the treatment of Pompe disease; and AT3375 and afegostat tartrate that are in preclinical studies used for treating Gaucher disease. The company has strategic collaboration with GlaxoSmithKline PLC to develop and commercialize migalastat HCl. Amicus Therapeutics, Inc. was founded in 2002 and is based in Cranbury, New Jersey.
Medicine Biopharmaceutical Rare Diseases Inborn Errors Of Metabolism Orphan Drugs Enzyme Replacement Therapy Fabry Disease Gaucher Disease Pompe Disease Lipid Storage Disorders Lysosomal Storage Disorders Protein Folding Treatment Of Pompe Disease
Is FOLD a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 17.62
52 Week Low 8.27
Average Volume 3,071,423
200-Day Moving Average 12.7499
50-Day Moving Average 12.1296
20-Day Moving Average 12.962
10-Day Moving Average 13.465
Average True Range 0.5719
ADX 30.12
+DI 29.7668
-DI 15.3724
Chandelier Exit (Long, 3 ATRs ) 12.7743
Chandelier Exit (Short, 3 ATRs ) 12.6407
Upper Bollinger Band 14.7189
Lower Bollinger Band 11.2051
Percent B (%b) 0.64
BandWidth 27.108471
MACD Line 0.5284
MACD Signal Line 0.5308
MACD Histogram -0.0024
Fundamentals Value
Market Cap 2.22 Billion
Num Shares 165 Million
EPS -1.47
Price-to-Earnings (P/E) Ratio -9.16
Price-to-Sales 135.92
Price-to-Book 7.22
PEG Ratio -0.17
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.90
Resistance 3 (R3) 13.91 13.77 13.82
Resistance 2 (R2) 13.77 13.66 13.77 13.80
Resistance 1 (R1) 13.62 13.59 13.55 13.61 13.77
Pivot Point 13.48 13.48 13.45 13.48 13.48
Support 1 (S1) 13.33 13.37 13.26 13.32 13.15
Support 2 (S2) 13.19 13.30 13.19 13.12
Support 3 (S3) 13.04 13.19 13.10
Support 4 (S4) 13.03